ClinicalTrials.gg
CompletedNCT04554966Updated Mar 4, 2024

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

A Phase 1 interventional study of ABBV-382 and ABBV-382 in Human Immunodeficiency Virus (HIV), sponsored by AbbVie. Completed at 21 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-04.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV infection is considered to be a chronic disease requiring lifelong therapy. This study will evaluate how safe ABBV-382 is and how it is absorbed, distributed and eliminated from the body in adult participants with HIV-1 infection.

ABBV-382 is an investigational drug being developed for the treatment of HIV-1 infection. This study takes place in 2 parts. In Part A, participants with HIV-1 and no history of combination antiretroviral therapy (cART) or who are off cART for more than 3 months will be enrolled to receive ABBV-382. In Part B, participants with no virus in their blood and on maintenance cART will be enrolled into one of the intravenous (IV) or subcutaneous (SC) groups. In the IV groups, participants will receive either placebo or ABBV-382 whereas participants in the SC group will receive ABBV-382. There is 1 in 3 chance that participants will receive placebo (no drug) in Part B IV groups. The IV group in Part B is double-blinded which means neither the study doctors nor the participants will know who will be given study drug or placebo. Around 52 adult participants with HIV-1 infection will be enrolled at approximately 21 sites across the United States, including Puerto Rico.

Participants in Part A will receive an intravenous (IV) dose of ABBV-382 on Day 1. Participants in Part B will receive an IV or SC dose of ABBV-382 or placebo on Days 1, 29 and 57.

There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and presence of side effects.

02

Conditions studied

  • Human Immunodeficiency Virus (HIV)

Browse trials for

Keywords

  • Human Immunodeficiency Virus
  • HIV
  • HIV-1
  • ABBV-382
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 54 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) is >= 18.0 to \<= 35.0 kg/m\^2 after rounding to the tenths decimal.
  • Must agree to use effective barrier protection during sexual activity for protection against (HIV)-1 transmission through the last study visit.
  • Female participants of must give consent to abide by requirements.
  • of >= 350 cells/μL at screening and at least once during the 48 weeks prior to screening.
  • Negative screen for drugs of abuse and alcohol at screening. Participants with a positive marijuana screen may be included after evaluation by the investigator that the use would not interfere with adherence to study requirements, and that usage is not on a regular or chronic basis.
  • Laboratory values must meet the acceptable criteria.

Part A participants must also have:

  • Positive test result for anti-HIV antibody at screening.
  • Plasma HIV-1 ribose nucleic acid (RNA) between 1,000 - 200,000 copies/mL at screening.
  • Must be naive to combination antiretroviral therapy (cART) or have been off of cART for > 12 weeks or 5 half-lives of the drug (whichever is longer) prior to screening with documentation of at least one plasma HIV-1 RNA measurement greater than or equal to the lower limit of quantification (LLOQ) during the off cART period.
  • Willing to hold on initiation of cART throughout the screening period and until 4 weeks after dosing.

Part B participants must also have:

  • Positive test result for anti-HIV antibody at screening.
  • Must have plasma HIV-1 RNA below the lower limit of quantification at screening and at least 24 weeks prior to screening. A single unconfirmed "blip" is allowed if preceded and followed by values below the lower limit of quantification.
  • Must be HIV-1 infected on cART for at least 48 weeks prior to screening and on current cART regimen for at least 12 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Female participants who are pregnant, breastfeeding, or considering becoming pregnant during the study.
  • History or ongoing diagnosis of acquired immune deficiency syndrome (AIDS)-defining illness.
  • History of or active immunodeficiency (other than ).
  • Active disease or history of autoimmune disease that has required systemic treatment.
  • medical disorders (other than HIV-1 infection) that might expose the participant to undue risk of harm, confound study outcomes, or prevent the participant from completing the study.
  • Active or suspected or history of malignancy (other than basal cell skin cancer or cervical carcinoma in situ) in the past 5 years.
  • History or evidence of active tuberculosis (TB) disease or untreated latent TB infection at screening.
  • No history of positive TB skin test or interferon gamma release assay (IGRA) or at screening which is considered clinically significant by the investigator. Participant with a history of a positive TB skin test or IGRA or at screening must have documentation of completion of a Centers for Disease Control and Prevention (CDC) recommended treatment course for latent TB. Any participant with suspicion for or diagnosis of active TB is excluded.
  • Known psychiatric or substance abuse disorders that would interfere with adherence to study requirements.
  • Currently enrolled in another interventional clinical study.
  • Received immunomodulatory or (including intravenous [IV]/oral [PO] at any dose, but excluding steroids that are inhaled or topical) therapy within 24 weeks prior to the first dose of study drug.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Part A: ABBV-382 Dose A

    Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.

    Drug: ABBV-382

  • Experimental
    Part A: ABBV-382 Dose B

    Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.

    Drug: ABBV-382

  • Experimental
    Part B: Intravenous Cohort: ABBV-382 Dose A

    Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.

    Drug: ABBV-382

  • Placebo comparator
    Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A

    Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.

    Drug: Placebo for ABBV-382

  • Experimental
    Part B: Intravenous Cohort: ABBV-382 Dose B

    Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.

    Drug: ABBV-382

  • Placebo comparator
    Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B

    Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.

    Drug: Placebo for ABBV-382

  • Experimental
    Part B: Subcutaneous Cohort: ABBV-382

    Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.

    Drug: ABBV-382

Interventions

  • Intravenous (IV) infusion

  • Subcutaneous (SC) injection

  • DrugPlacebo for ABBV-382

    Intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Incidence of Study Drug-Related Grade 3 or Higher Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either "Reasonable Possibility" or "No Reasonable Possibility" and will assess the severity of each adverse event from Grade 1 (mild) to Grade 4 (potentially life-threatening).

    Time frame: Up to Day 255

  2. Maximum Observed Serum Concentration (Cmax) of ABBV-382 (Part A and Part B)

    Maximum observed serum concentration (Cmax) of ABBV-382.

    Time frame: Up to Day 225

  3. Time to Cmax (Tmax) of ABBV-382 (Part A and Part B)

    Time to Cmax (Tmax) of ABBV-382.

    Time frame: Up to Day 225

  4. Area Under the Serum Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-382 (Part A)

    Area under the serum concentration-time curve (AUC) from time 0 to the time of last measurable concentration (AUCt) of ABBV-382.

    Time frame: Up to Day 112

  5. Area Under the Serum Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-382 (Part A)

    AUC from time 0 to infinite time (AUCinf) of ABBV-382.

    Time frame: Up to Day 112

  6. Terminal Phase Elimination Rate Constant (β) of ABBV-382 (Part A)

    Terminal phase elimination rate constant of ABBV-382.

    Time frame: Up to Day 112

  7. Terminal Phase Elimination Half-Life (t1/2) of ABBV-382 (Part A)

    Terminal phase elimination half-life of ABBV-382.

    Time frame: Up to Day 112

  8. Observed Concentration at the End of the 4-Week Dosing Interval (Ctrough) of ABBV-382 (Part B)

    Observed concentration at the end of the 4-week dosing interval (Ctrough) of ABBV-382.

    Time frame: Up to Day 225

  9. AUC During the 4-Week Dosing Interval (AUCtau) of ABBV-382 (Part B)

    AUC during the 4-week dosing interval (AUCtau) of ABBV-382.

    Time frame: Up to Day 225

  10. Terminal Phase Elimination Half-Life (t1/2) of ABBV-382 (Part B)

    Terminal phase elimination half-life (t1/2) of ABBV-382 will be estimated after the third dose only.

    Time frame: Day 57 to Day 225

07

Study locations

21 sites
  • Franco Felizarta, Md /Id# 223815
    Bakersfield, California 93301, United States
  • Ruane Clinical Research Group /ID# 224125
    Los Angeles, California 90036, United States
  • Quest Clinical Research /ID# 223347
    San Francisco, California 94115-3037, United States
  • George Washington University Medical Faculty Associates /ID# 223493
    Washington, District of Columbia 20037-3201, United States
  • Midway Immunology and Research Center /ID# 223500
    Fort Pierce, Florida 34982, United States
  • Orlando Immunology Center /ID# 223498
    Orlando, Florida 32803, United States
  • St. Joseph Comprehensive Research Institute /ID# 246232
    Tampa, Florida 33614-7112, United States
  • Triple O Research Institute /ID# 223460
    West Palm Beach, Florida 33407-3100, United States
  • CenExcel iResearch LLC /ID# 225526
    Decatur, Georgia 30030, United States
  • Infinite Clinical Trials - Morrow /ID# 225455
    Morrow, Georgia 30260-2342, United States
  • University of Iowa Hospitals and Clinics /ID# 224267
    Iowa City, Iowa 52242, United States
  • Be Well Medical Center /ID# 223381
    Berkley, Michigan 48072-3046, United States
  • North Shore University Hospital Manhasset /ID# 223343
    Manhasset, New York 11030-3816, United States
  • The Christ Hospital /ID# 224871
    Cincinnati, Ohio 45219, United States
  • Central Texas Clinical Research /ID# 223378
    Austin, Texas 78705-3326, United States
  • Prism Health North Texas - Oak Cliff Health Center /ID# 223237
    Dallas, Texas 75208-4599, United States
  • North Texas Infectious Diseases Consultants, P.A /ID# 223236
    Dallas, Texas 75246, United States
  • The Crofoot Research Center, Inc /ID# 223383
    Houston, Texas 77098-3900, United States
  • Peter Shalit, M.D. /ID# 224252
    Seattle, Washington 98104-3595, United States
  • Ponce Medical School Foundation /ID# 224231
    Ponce, 00716-0377, Puerto Rico
  • Clinical Research Puerto Rico /ID# 223923
    San Juan, 00909, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2023, 27 months.

Of 76 industry-sponsored phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 27 months is above that.

Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Sep 18, 2020
StartActual
Apr 16, 2021
Primary completionActual
Aug 14, 2023
CompletionActual
Aug 14, 2023
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04554966
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 18, 2020
Start date
Apr 16, 2021
Primary completion
Aug 14, 2023
Completion
Aug 14, 2023
Last update
Mar 4, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trosunilimab

Start the discussion